Trial Profile
Phase II clinical trial of intra-lesional administration of TG1042 (adenovirus-interferon-gamma) in patients with relapsing primary cutaneous B-cell lymphomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs TG 1042 (Primary)
- Indications Cutaneous B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Transgene
- 07 Dec 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
- 20 Dec 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.